[go: up one dir, main page]

ATE298371T1 - Nicht-primaten lentivirale vektoren und verpackungssysteme - Google Patents

Nicht-primaten lentivirale vektoren und verpackungssysteme

Info

Publication number
ATE298371T1
ATE298371T1 AT98948216T AT98948216T ATE298371T1 AT E298371 T1 ATE298371 T1 AT E298371T1 AT 98948216 T AT98948216 T AT 98948216T AT 98948216 T AT98948216 T AT 98948216T AT E298371 T1 ATE298371 T1 AT E298371T1
Authority
AT
Austria
Prior art keywords
cells
packaging
vectors
lentiviral vectors
primate lentiviral
Prior art date
Application number
AT98948216T
Other languages
English (en)
Inventor
Eric M Poeschia
David J Looney
Flossie Wong-Staal
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE298371T1 publication Critical patent/ATE298371T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Laminated Bodies (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Adhesive Tapes (AREA)
  • Wrappers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98948216T 1997-09-24 1998-09-15 Nicht-primaten lentivirale vektoren und verpackungssysteme ATE298371T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93663397A 1997-09-24 1997-09-24
PCT/US1998/019162 WO1999015641A1 (en) 1997-09-24 1998-09-15 Non-primate lentiviral vectors and packaging systems

Publications (1)

Publication Number Publication Date
ATE298371T1 true ATE298371T1 (de) 2005-07-15

Family

ID=25468901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98948216T ATE298371T1 (de) 1997-09-24 1998-09-15 Nicht-primaten lentivirale vektoren und verpackungssysteme

Country Status (9)

Country Link
US (2) US6555107B2 (de)
EP (1) EP1017797B1 (de)
JP (1) JP2001517433A (de)
AT (1) ATE298371T1 (de)
AU (1) AU747438B2 (de)
CA (1) CA2304983A1 (de)
DE (1) DE69830663T2 (de)
ES (1) ES2245042T3 (de)
WO (1) WO1999015641A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
GB2345062B (en) * 1997-12-22 2001-07-25 Oxford Biomedica Ltd Retroviral vectors
CA2315269A1 (en) * 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
CA2318575A1 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
EP1103615A1 (de) * 1999-11-25 2001-05-30 Universite De Geneve Vektoren, die nicht-teilende Zellen immortalisieren können und Zellen, die mit diesen Vektoren immortalisiert wurden
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
ES2340073T3 (es) * 1999-12-14 2010-05-28 Novartis Ag Vectores basados en virus de inmunodeficiencia bovina (vib).
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
JP4689144B2 (ja) * 2001-02-22 2011-05-25 ノバルティス アーゲー 眼球血管新生を処置するための方法
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
SI1448246T2 (sl) 2001-11-19 2015-12-31 Scil Technology Gmbh Postopek za proizvodnjo homogeno obložene naprave, ki ima osteoinduktivne in osteokonduktivne lastnosti
AU2003225544A1 (en) * 2002-02-04 2003-09-02 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
EP1534751B1 (de) * 2002-08-28 2010-04-14 Novartis AG Gentherapie des auges
WO2004024199A1 (en) * 2002-09-10 2004-03-25 Scil Technology Gmbh Metal implant coated under reduced oxygen concentration with osteoinductive protein
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
KR101162970B1 (ko) * 2003-10-08 2012-07-12 테리온 바이오로직스, 인크. 변형된 ｃｅａ/ｂ7 벡터
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
WO2005079836A1 (en) 2004-02-18 2005-09-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
WO2005079829A2 (en) * 2004-02-18 2005-09-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
US20060199266A1 (en) * 2004-08-12 2006-09-07 Vectorcore A Co., Ltd. CAEV-based vector systems
WO2006089001A2 (en) 2005-02-16 2006-08-24 Lentigen Corporation Lentiviral vectors and their use
US20070092883A1 (en) * 2005-10-26 2007-04-26 De Luwe Hoek Octrooien B.V. Methylation specific multiplex ligation-dependent probe amplification (MS-MLPA)
US11859168B2 (en) 2007-05-29 2024-01-02 Christopher B. REID Electroporation, developmentally-activated cells, pluripotent-like cells, cell reprogramming and regenerative medicine
BRPI0810949A2 (pt) * 2007-05-29 2015-10-27 Christopher B Reid "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método"
ES2662030T3 (es) 2007-10-15 2018-04-05 Admedus Vaccines Pty Limited Sistema de construcciones y usos para el mismo
JP2011503207A (ja) 2007-11-16 2011-01-27 サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
AU2011336467A1 (en) 2010-12-01 2013-07-04 Spinal Modulation, Inc. Agent delivery systems for selective neuromodulation
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
US9730996B2 (en) 2012-10-24 2017-08-15 Texas Biomedical Research Institute Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
WO2015066796A1 (en) * 2013-11-06 2015-05-14 Nexen Energy Ulc Processes for producing hydrocarbons from a reservoir
EP2871233A1 (de) 2013-11-12 2015-05-13 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur Herstellung von biogenen Stoffen
CA3006779A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
CN111630170A (zh) 2017-07-31 2020-09-04 映像生物有限公司 眼部疾病的细胞模型及用于眼部疾病的疗法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
AU2021358957A1 (en) 2020-10-07 2023-06-08 AskBio Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
DE102023102366A1 (de) 2023-01-31 2024-08-01 BRANDENBURGISCHE TECHNISCHE UNIVERSITÄT COTTBUS-SENFTENBERG, Körperschaft des öffentlichen Rechts Testsystem aufweisend stabil CYP-transfizierte oder transduzierte Säugetierzellen

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
CA2109579A1 (en) 1991-05-29 1992-12-10 Julianna Lisziewicz Eukaryotic expression vectors with regulation of rna processing
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
JP3285355B2 (ja) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｖｏ遺伝子治療のための方法及び組成物
PT702723E (pt) 1993-04-21 2003-01-31 Pasteur Institut Implante biocompativel para a expressao e a secrecao in vivo de um composto terapeutico
AU680921B2 (en) 1993-05-17 1997-08-14 Regents Of The University Of California, The Ribozyme gene therapy for HIV infection and AIDS
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
WO1995025547A1 (en) 1994-03-24 1995-09-28 University Of Washington Devices and methods for implanting transduced cells
EP0752000A1 (de) * 1994-03-24 1997-01-08 Syngenix Limited Verpackungsunfähige lentiviren
EP0759471A4 (de) 1994-05-10 1997-10-15 Hisamitsu Pharmaceutical Co Rekombinanter vektor bestehend aus dem menschlichen immunschwäche-virus und verfahren zu seiner herstellung
WO1995032300A1 (en) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
DK0817858T3 (da) 1995-03-09 2003-08-11 Gsf Forschungszentrum Umwelt Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
GB9517263D0 (en) 1995-08-23 1995-10-25 Cancer Res Campaign Tech Expression systems
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9525639D0 (en) * 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
WO1997032983A1 (en) 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
ATE424463T1 (de) 1996-05-06 2009-03-15 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
AU3212197A (en) 1996-06-20 1998-01-07 Salk Institute For Biological Studies, The Modular assembly retroviral vectors and uses thereof
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
AU741747B2 (en) * 1997-05-13 2001-12-06 University Of North Carolina At Chapel Hill, The Lentivirus-based gene transfer vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318575A1 (en) 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors

Also Published As

Publication number Publication date
WO1999015641A1 (en) 1999-04-01
EP1017797A4 (de) 2003-04-16
US20030012769A1 (en) 2003-01-16
DE69830663D1 (de) 2005-07-28
EP1017797A1 (de) 2000-07-12
US6555107B2 (en) 2003-04-29
AU747438B2 (en) 2002-05-16
ES2245042T3 (es) 2005-12-16
JP2001517433A (ja) 2001-10-09
EP1017797B1 (de) 2005-06-22
US20010016347A1 (en) 2001-08-23
DE69830663T2 (de) 2006-05-11
AU9483798A (en) 1999-04-12
CA2304983A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
ATE298371T1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
FI963070A0 (fi) Klooripyrimidiinivälituotteita
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
CY1111504T1 (el) Αζαδικυκλοαλκανια ως ρυθμιστες του ccr5
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
ES2143641T3 (es) Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
ES2012129A6 (es) Un metodo para la obtencion de fragmentos de cd4 humana biologicamenteactivos.
TR199801395A2 (xx) Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�.
ATE475713T1 (de) Trans-lentivirales vektor system
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
ATE361359T1 (de) Funktion und aktivität des viralen proteins r (vpr)
EP1070122A4 (de) Induktion apoptischer oder zytotoxischer genexpression durch adenovirus-vermittelten gen-kotransfer
ATE238427T1 (de) Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DK0697875T3 (da) Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
ATE247978T1 (de) Verwendung von ompa enterobakterproteinen um zielgerichtet antigen-präsentierende zellen anzusteuern
MX9700560A (es) Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
ATE292174T1 (de) Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017797

Country of ref document: EP

REN Ceased due to non-payment of the annual fee